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Abstract
Background The natural history of facioscapulohumeral muscular dystrophy (FSHD) is undefined.
Methods An observational cohort study was conducted in 246 FSHD1 patients. We split the analysis between index cases 
and carrier relatives and we classified all patients using the Comprehensive Clinical Evaluation Form (CCEF). The dis-
ease progression was measured as a variation of the FSHD score performed at baseline and at the end of 5-year follow-up 
(ΔFSHD score).
Findings Disease worsened in 79.4% (112/141) of index cases versus 38.1% (40/105) of carrier relatives and advanced more 
rapidly in index cases (ΔFSHD score 2.3 versus 1.2). The 79.1% (38/48) of asymptomatic carriers remained asymptomatic. 
The highest ΔFSHD score (1.7) was found in subject with facial and scapular weakness at baseline (category A), whereas 
in subjects with incomplete phenotype (facial or scapular weakness, category B) had lower ΔFSHD score (0.6) p < 0.0001.
Conclusions The progression of disease is different between index cases and carrier relatives and the assessment of the CCEF 
categories has strong prognostic effect in FSHD1 patients.
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Abbreviations
CCEF  Comprehensive Clinical Evaluation Form
DRA  D4Z4 reduced alleles
FSHD  Facioscapulohumeral muscular dystrophy
INRF  Italian National Registry for FSHD
INCF  Italian National Consortium for FSHD
MRC  Medical Research Council
NIV  Non-invasive ventilation
Introduction
Facioscapulohumeral muscular dystrophy (FSHD, OMIM 
# 158900) is a hereditary myopathy with prevalence of 1 in 
8500–20,000 individuals [1, 2]. The classical FSHD pheno-
type is characterized by a distinctive distribution of muscular 
weakness [3].
Two genetically distinct disease subtypes, FSHD1 and 
FSHD2 have been described. The vast majority of FSHD 
subjects, named FSHD1, carry contractions of a polymor-
phic tandemly arrayed 3.3 kb D4Z4 repeat element on the 
telomeric region of chromosome 4, at 4q35 [4]. Detection 
of one D4Z4 alleles with 10 or fewer repeats associated with 
the 4qA polymorphism is considered a molecular hallmark 
for FSHD diagnosis [5]. FSHD2, which represents 5–10% of 
cases, is contraction-independent, with affected individuals 
carrying two D4Z4 arrays in the healthy range (> 10 RUs) 
[6].
Since the discovery of the D4Z4 locus for FSHD diagno-
sis it was clear that many different phenotypes and reduced 
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penetrance [7–17] can be observed in people carrying a 
D4Z4 reduced allele (DRA). These features have substan-
tially hindered the possibility of defining the progression 
modes and the natural history of FSHD [18, 19] with critical 
consequences on clinical management. The few studies that 
attempted the description of the FSHD natural history con-
firmed the considerable variability with several difficulties 
to identify a marker that may serve as predictor of decline 
[16, 18–20].
In previous studies we designed the FSHD clinical score, 
a tool to capture the degree of clinical disability, and the 
Comprehensive Clinical Evaluation Form (CCEF) for the 
standardized description of clinical phenotypes [21, 22]. 
Recently, through the use of the CCEF we clarified that there 
is a clinical phenotypic spectrum in molecularly homogene-
ous genetic subgroups. In particular, carriers of 7–8 DRA, 
until now considered in the classical FSHD range, present a 
clinical variability that is quite similar to that found among 
subjects carrying one 9 -10 DRA [9], which are instead con-
sidered borderline alleles [11]. Some genotype–phenotype 
studies suggest carriers 7–10 DRA have a low penetrance 
and, in this subgroup, the muscular impairment of carriers 
relatives is less severe than index cases [9, 17, 20]. By con-
trast carriers of 1–3 DRA present less significant differences 
[8]. Moreover, subjects with a facial and scapular involve-
ment are more severely affected than subjects with facial 
sparing myopathy [23, 24]. All these observations suggest 
that disease progression can differ on the basis of size of 
DRA, degree of kindship or phenotypic features.
Here we report the results of a multi-centric longitudinal 
cohort study of 246 subjects from the Italian National Regis-
try for FSHD (INRF) database. We reviewed the phenotypic 
characteristics of index cases and carrier relatives carrying 
one DRA within the size range of 1–10 Repeat Units (RUs) 
at baseline and after 5-year follow-up. To model the long-
term disease progression, we analyzed how sex, DRA size, 
age at onset, disease duration, and clinical phenotype affect 
the progression rate in index cases and carrier relatives.
Methods
Study design and participants
Our multi-centric longitudinal cohort study was performed 
in 14 Italian FSHD-experienced centers of the Italian Clini-
cal Network for FSHD (ICNF). 246 Caucasian individuals 
(141 index cases and 105 carrier relatives from 63 family) 
from a consecutive group were enrolled between January 
10th, 2007 and December 20th, 2011 for the baseline visit. 
All individuals included in this study carry one DRA within 
the size range of 1–10 repeat units (RU) associated with 
the permissive haplotype 4qA. We considered a follow-up 
period of 5 years; therefore, the last visit was performed 
between February, 2012 and December, 2016. We enrolled 
only patients for which the last clinical evaluation has been 
performed using the CCEF, applied by a properly trained 
physician of the INCF. The 5-year time of the clinical fol-
low-up was considered a significant period in which the dis-
ease may evolve or appear in healthy carrier relatives. In ten 
out of 14 centers, individuals were evaluated by the same 
investigators at all visits, whereas in the remaining centers 
evaluators changed for a subset of patients.
Clinical investigation
The Comprehensive Clinical Evaluation Form (CCEF) [21] 
was used to classify all DRA carriers. The CCEF divides the 
carriers as following: (1) individuals presenting facial and 
scapular girdle muscle weakness typical of FSHD (category 
A, subcategories A1–A3), (2) individuals with muscle weak-
ness limited to scapular girdle or facial muscles (category B 
subcategories B1, B2), (3) asymptomatic/healthy individu-
als (category C, subcategories C1, C2), (4) individuals with 
myopathic phenotype presenting clinical features not con-
sistent with FSHD canonical phenotype (D, subcategories 
D1, D2).
As primary outcome measure, we used the ΔFSHD score 
obtained by comparing the FSHD score at baseline and at 
follow-up. Disease progression was assessed as increment of 
the FSHD score [22]. The FSHD score ranges from 0, when 
no objective sign of functional impairment is present, to 15, 
when all tested muscle groups are severely impaired and 
patient is wheel-chair dependent (see https ://www.fshd.it for 
training). The evaluation protocol is specifically designed for 
FSHD. Each section describes the functional evaluation of 
six muscle districts peculiarly affected in FSHD: face (score 
0–2); shoulder girdle (score 0–3); upper limbs (score 0–2); 
distal legs (score 0–2); pelvic girdle (score 0–5); abdominal 
muscles (score 0–1). Diversely from the commonly used 
Clinical Severity Scale (CSS) [10], this protocol attributes 
an independent score to each distinct muscle group thus pro-
viding an accurate description of the distribution of muscle 
weakness for each individual.
In addition, we evaluated the strength of ten different 
muscle groups on both right and left side using the Medical 
Research Council (MRC) grading scale (0–5) [25–28]: fore-
arm flexor/extensor muscles, hand and wrist flexor/extensor 
muscles, thigh flexor, knee extensor, and foot extensor/flexor 
muscles. The MRC evaluation was carried out by a neurolo-
gist previously trained in clinical trials using this methodol-
ogy [29]. All tests and evaluations were performed in a blind 
manner with respect to the results of the D4Z4molecular 
analysis. A very good inter-rater reliability of assessment 
has been shown in our previous studies testing our clinical 
evaluation methodology [21, 22].
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Age at onset and the first muscle group affected by dis-
ease were derived from patients’ records or recollections 
[30]. Individuals were asked some questions to retrieve 
more accurate information that have been proved relevant 
or indicative for FSHD.
The INRF database was approved by the ethics committee 
of the Province of Modena. Informed written consent was 
obtained from all study participants, in accordance with the 
ethical standards of the 1964 Declaration of Helsinki.
Molecular characterization
DNA was prepared from isolated lymphocytes according 
to standard procedures. Restriction endonuclease digestion 
of DNA was performed with the appropriate restriction 
enzyme: EcoRI, EcoRI/BlnI. Digested DNA was separated 
by pulsed field gel electrophoresis (PFGE) in 1% agarose 
gels, as previously described [31] and by linear 0.4% gel 
electrophoresis. Allele sizes and the presence or absence 
of the 4qA allele were estimated by Southern hybridization 
with probes p13E-11 and 4qA, respectively, run with High 
Molecular Weight Marker and 2.5 kb DNA ladder. Restric-
tion fragments were detected by autoradiography.
Statistical analysis
Baseline characteristics of the study cohort for index cases 
and carrier relatives were summarized with mean and stand-
ard deviation for quantitative variables and frequencies dis-
tribution for qualitative variables. To evaluate differences 
between index cases and carrier relatives with respect to 
quantitative variables we used the t test, while chi-square test 
was used to evaluate whether the distribution of qualitative 
variables was similar in index cases and carrier relatives. 
Same tests were used to compare quantitative and categori-
cal variables on females and males. We used one-way analy-
sis of variance (ANOVA) to evaluate whether size of the 
DRA or CCEF clinical classification were associated with 
FSHD and ΔFSHD score. The ANOVA was also used to 
evaluate the associations between age at onset and FSHD 
score and ΔFSHD score. To evaluate the impendent associa-
tion of the size of the DRA and CCEF clinical classification 
with ΔFSHD score a multivariable regression model was fit-
ted adjusting for age, sex, FSHD score at baseline and length 
of follow-up. Missing values were not imputed.
Data availability
The data that support the findings of this study are available 
upon request at miogenlab@unimore.it.
Results
General findings
The study population consisted of 246 individuals carrying 
one DRA, 141 index cases, 84 (59.6%) males, and 105 carrier 
relatives from 63 families, 52 (49.5%) males. Demographics, 
molecular and clinical data are given in Table 1. At baseline, 
the average age of index cases was 46.1 ± 14.2 years; that of 
carrier relatives was 38.3 ± 15.6 years. The average duration 
of follow-up of index cases was 6.1 ± 1.2 years; that of car-
rier relatives was 5.8 ± 0.9 years.
The duration of disease (calculated from the onset of 
the first symptoms to the first examination at time 0) var-
ies between 0 and 54 years (mean time 20.5 ± 14.3 years) 
for index cases and between 0 and 41 years (mean time 
10.0 ± 11.5 years) for carrier relatives.
At onset, 133 individuals (66.8%) reported weakness of 
scapular girdle muscles, 23 (11.6%) reported facial muscle 
weakness, 6 (3.0%) pelvic girdle weakness, 26 (13.1%) lower 
limb involvement (foot drop). Eleven patients (5.5%) did not 
report any symptom but at their first examination seven pre-
sented mild facial weakness, one had isolated scapular girdle 
weakness, two suffered from scapular girdle weakness asso-
ciated with lower limb involvement. Age at onset was sig-
nificantly different between females and males (29.6 ± 14.3, 
and 24.2 ± 16.4, respectively; p = 0.014). At baseline, three 
Table 1  Cohort characteristics at baseline
a Calculated on 58 carrier relatives with FSHD symptoms at baseline 
examination
Index cases (n = 141) Carrier 
relatives 
(n = 105)
n (%) n (%)
Men 84 (59.6) 52 (49.5)
Mean (SD) Mean (SD)
Age (years) 46.1 (14.2) 38.3 (15.6)
Age at onset (years) 25.7 (14.8) 29.0 (16.5)a
Disease duration (years) 20.5 (14.3) 10.0 (11.5)a
D4Z4 allele size (RU) n (%) n (%)
 1–3 12 (8.5) 4 (3.8)
 4–5 37 (26.2) 26 (24.8)
 6 41 (29.1) 39 (37.1)
 7–8 29 (26.6) 16 (15.2)
 9–10 22 (15.6) 20 (19.1)
FSHD score n (%) n (%)
 0 1 (0.8) 47 (44.8)
 1–2 18 (12.8) 31 (29.5)
 3–7 75 (53.2) 25 (23.8)
 8–15 47 (33.3) 2 (1.9)
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individuals (1.2%) were not ambulant; one individual (0.4%) 
was on non-invasive ventilation (NIV). At the end of follow-
up period seven index cases (5%) and one relative (1%) lost 
ambulation and five index cases had started NIV (3.3%).
FSHD score at baseline
Disease severity was defined by the FSHD score. At base-
line, in index cases the mean FSHD score was 6.3 ± 3.3, in 
carrier relatives 1.8 ± 2.5. As shown in Table 1, at baseline 
one index case out of 141 (0.8%) showed slight increase 
(2 ×) of blood creatine kinase, diffuse myalgias and early 
fatigability without functional motor impairment, 18 index 
cases (12.8%) were minimally affected (FSHD score 1–2); 
75 (53.2%) were moderately affected (FSHD score 3–7); 47 
(33.3%) were severely affected (FSHD score 8–15). Among 
the 105 carrier relatives, 47 (44.8%) were healthy (FSHD 
score 0); 31 (29.5%) were minimally affected individuals; 25 
(23.8%) were moderately affected, two (1.9%) were severely 
affected.
Variation of the FSHD score at follow‑up (ΔFSHD 
score)
We evaluated the extent of disease progression, measur-
ing the increment of the FSHD score (ΔFSHD score) at 
Fig. 1  a Distribution Δ FSHD 
score of between index cases 
and carriers relatives. The 
percentage of index cases or 
carriers relatives with 5 dif-
ferent sets of Δ FSHD score is 
presented. b Proposed disease 
trajectories of index cases 
and carriers relatives. These 
trajectories describe the func-
tional decline measured by the 
FSHD score in index cases and 
carriers relatives. Index cases 
received a higher FSHD score at 
baseline than carriers relatives. 
The ΔFSHD score is higher in 
index cases than carriers rela-
tives. Data are represented as 
mean ± CI. c Proposed disease 
trajectories of clinical category. 
The trajectories describe the 
functional decline measured 
by the FSHD score in clinical 
category A, B and D. Data are 
represented as mean ± CI
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follow-up. As shown Fig. 1a, the FSHD score of the first 
evaluation was maintained in 20.6% of index cases and 
61.9% of carrier relatives. In general, in our cohort we 
observed 1.3 (1.1; 1.4) increase in the FSHD score at the 
end of follow-up period (mean FSHD score 4.4 ± 3.8 SD at 
baseline versus mean FSHD score 5.7 ± 4.3 SD at follow-
up). The overall ΔFSHD score ranged widely between 0 
and 7, median 1. When we selected only affected individuals 
with FSHD score 1–14 (n 196), eliminating the three most 
severely impaired cases (FSHD score 15) and the ones with 
FSHD score 0, we observed an average ΔFSHD score of 1.5 
(1.3; 1.7) (mean FSHD score 5.4 ± 3.3 SD at baseline versus 
mean FSHD score 6.9 ± 3.8 SD at follow-up).
The separate evaluation of the ΔFSHD score in index 
cases and carrier relatives shows that the FSHD score 
increased of about 2 points in index cases (from 6.3 ± 3.3 
SD at baseline to 8.1 ± 3.6 SD at follow-up), whereas it 
increased in of approximately 0.6 point among carrier 
relatives (from 1.8 ± 2.6 SD at baseline to 2.4 ± 2.9 SD at 
follow-up). We compared the slope of disease progression 
of the index cases’ group with that of the carrier relatives’ 
group. Figure 1b shows that the disease trajectory of the 
index cases’ group is steeper than the one of their carrier 
relatives (associated p value < 0.001). This observation is 
confirmed by the regression model. We also compared the 
ΔFSHD score observed in females and males (1.13 ± 1.24 
versus 1.39 ± 1.57) and found no evidence of differences in 
disease progression between the two sexes.
Correlation of ΔFSHD and the clinical category
The distribution of clinical categories and subcategories 
in our cohort is shown in Supplementary Table 1: 152 
(62.1%) individuals displayed the involvement of facial and 
scapular girdle muscles and were classified as category A. 
Clinical category A was much more represented in index 
cases than in carrier relatives [115 (81%) versus 37 (35%), 
respectively]. Whereas the incomplete phenotype (clinical 
category B) was more frequent in carrier relatives than in 
index cases (25% versus 6%) (p < 0.001). Age at onset was 
not significantly different between index cases and carrier 
relatives subdivided on the basis of the clinical subcatego-
ries (p = 0.5209) (Supplementary Table 1). We observed that 
79.1% (38/48) of carriers without motor impairment (clinical 
category C) and 57.4% (27/47) of individuals with mild disa-
bility (FSHD score ≤ 2) had ΔFSHD score 0. Figure 2 shows 
that the distribution of clinical categories among index cases 
or carrier relatives is not associated with a particular size of 
DRA. Instead, we found that clinical category A is associ-
ated with higher FSHD score at baseline and steeper slope 
of disease progression (average FSHD score at baseline 6.1, 
ΔFSHD score 1.7) as clinical category D (average FSHD 
score 4.2, ΔFSHD score 1.6), whereas we observed slower 
disease progression in individuals with incomplete clinical 
phenotype (category B, average FSHD score at baseline 1.7, 
ΔFSHD score 0.6, p < 0.0001) (Fig. 1c).
Correlation of ΔFSHD and DRA size
To estimate whether the size of DRA is a predictor of dis-
ease severity and progression, we analyzed the FSHD score 
and the ΔFSHD score observed in individuals carrying DRA 
of different size. Table 2a shows that the highest basal FSHD 
score was detected in the index cases carrying DRA with 
1–3 RU, whereas it was lower and did not significantly vary 
among index cases carrying DRA with 4–10 RU. Table 2b 
shows that the ΔFSHD score of all index cases did not sig-
nificantly vary on the basis of the DRA size. We observed 
that in the group carrying DRA with 4–10 RU index cases 
have higher ΔFSHD score than carrier relatives (p < 0.01), 
whereas we found no difference between index cases and 
carrier relatives carrying DRA with 1–3 RU (p = 0.831).
Fig. 2  Distribution of index 
cases and carriers relatives 
carrying D4Z4 reduced allele 
according to D4Z4 allele size 
(RU) and clinical categories. 
Subjects were subdivided by 
D4Z4 reduced allele size: 1–3, 
4–5, 6, 7–8, 9–10 repeat units. 
In each subgroup, number 
of index cases and carriers 
relatives who were assessed as 
clinical category A, B, C or D 
are reported
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Correlation of ΔFSHD and age at onset
We also investigated whether age at disease onset correlates 
with disease outcome. We considered age at examination, 
disease duration, FSHD score and ΔFSHD score. As shown 
in Table 3, in our cohort disease onset by age 10 is not asso-
ciated with more severe disease outcome (p = 0.706).
Evaluation of determinants of ΔFSHD score
We finally investigated the possible relationships between 
size of DRA, or clinical phenotype, described as clinical 
category, with disease progression considering age, sex, 
length of follow-up, and FSHD score at baseline. Table 4 
shows the results of the multivariable regression models 
that evaluate determinants of ΔFSHD score. The multi-
variable models confirm the strong prognostic effect of the 
size of the reduced D4Z4 and CCEF categories. Interest-
ingly, the effect is stronger on carrier relatives on which 
the prognostic model explains the 42% of ΔFSHD score 
variability. To be noted that the effect of the size of the 
reduced D4Z4 allele is mainly due to the difference of 
ΔFSHD score between carriers of 1–3 DRA versus 4–10 
DRA carriers. The effect of D4Z4 size among carriers of 
4–10 DRA, was not significantly different (p = 0.675 for 
index cases, p = 0.083 for carrier relatives). Instead, the 
multivariate analysis demonstrates that the effect of the 
size of the reduced D4Z4 allele is mainly responsible for 



















n (%) Mean (SD) Mean (SD) Mean (SD) n (%) Mean (SD) Mean (SD) Mean (SD)
1–3 12 (75.0) 39.4 (11.6) 9.6 (2.5) 11.8 (2.8) 4 (25.0) 20.2 (16.1) 3.0 (1.4) 5.5 (3.7)
4–5 37 (58.7) 43.4 (15.8) 6.9 (3.4) 8.6 (3.5) 26 (41.3) 40.1 (18.0) 2.8 (3.7) 2.6 (2.4)
6 41 (51.3) 46.6 (14.0) 6.3 (2.9) 7.9 (3.0) 39 (48.7) 35.0 (14.9) 1.5 (2.0) 2.4 (2.6)
7–8 29 (64.1) 47.5 (13.5) 5.8 (3.4) 7.3 (3.8) 16 (35.9) 41.4 (13.6) 2.4 (2.2) 2.7 (2.2)
9–10 22 (52.4) 51.4 (13.2) 4.6 (3.2) 6.6 (3.4) 20 (47.6) 43.4 (12.8) 0.5 (1.1) 0.8 (1.4)
Anova F test p 
value
0.012 0.001 0.0005 0.034 0.018 0.0043
B
D4Z4 allele size (RU) Δ FSHD score
Index cases Carrier relatives t test
Mean (SD) Mean (SD) p value
1–3 2.25 (1.76) 2.50 (2.64) 0.831
4–5 1.78 (1.65) 0.85 (0.83) 0.010
6 1.63 (1.43) 0.56 (0.99) 0.001
7–8 1.52 (1.21) 0.31 (0.87) 0.001
9–10 1.95 (1.68) 0.35 (0.67) 0.001
Anova F test p value 0.616 0.001
Table 3  Distribution of age, 
disease duration, FSHD score 
and Δ FSHD score, by age 
at onset on 198 subjects with 
FSHD at baseline examination









≤ 10 (24) 35.1 (17.6) 27.5 (17.5) 6.7 (4.2) 1.7 (2.0)
11–18 (58) 37.9 (14.7) 22.8 (14.2) 6.2 (3.7) 1.6 (1.4)
19–35 (56) 40.6 (13.2) 15.6 (13.0) 4.9 (3.2) 1.3 (1.4)
36–54 (48) 55.0 (7.6) 10.7 (7.7) 5.1 (2.7) 1.4 (1.1)
≥ 55 (12) 61.5 (13.2) 8.8 (15.4) 3.8 (3.2) 1.6 (1.8)
Anova F test p value p < 0.001 p < 0.001 0.024 0.706
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the difference of ΔFSHD score between carriers of 1–3 
DRA versus 4–10 DRA carriers.
MRC assessment
Figure Supplementary 1A shows that at baseline, muscle 
strength was preserved at neurological examination (MRC 
grade 5/5) in all muscle groups for the large majority of 
246 individuals. In particular, hand and wrist flexor/extensor 
muscles in 219 (89%), quadriceps in 190 (77.2%), brachialis 
biceps in 183 (74.4%), brachialis triceps 174 (70.7%) and 
tibialis anterior in 145 (58.9%).
Tibialis anterior and quadriceps femoris were signifi-
cantly more affected in index cases than in carrier relatives; 
35.5% of index cases versus 4.8% carrier relatives had MRC 
grade ≤ 3/5 of tibialis anterior (p < 0.0001 chi-square test) 
(Supplementary Figure 1B and 1C). In quadriceps femo-
ris 63.8% of index cases and 95.2% of carrier relatives had 
MRC grade 5/5 (p < 0.0001), while 8.5% of index cases 
and 1.9% carrier relatives had MRC grade ≤ 3/5 (p = 0.027) 
(Supplementary Figure 1D and 1E).
At follow-up the muscle strength of tibialis anterior had 
diminished in 30% of individuals, 70 index cases (49.6%) 
and 22 carrier relatives (20.1%) (Supplementary Figure 1B), 
whereas the strength in brachialis triceps and quadriceps 
femoris muscles were reduced at a significantly lesser extent 
(16.3% and 5.3%, respectively).
Discussion
FSHD is among the most common forms of muscular dys-
trophy with a considerable clinical heterogeneity also in 
genetically homogeneous cohorts [9, 11]. The study of 
natural history in a slowly and highly variable progressive 
disease such FSHD is crucial to identify sensitive, vali-
date and reliable outcome measures in designing clinical 
trial. However, the natural history of FSHD has not been 
well defined, with most information based on historical or 
retrospective data. At present, only two studies describe 
the FSHD natural history [18, 19]. Both studies highlight 
the considerable variability in the progression modes 
among carriers of the molecular defect. The reasons for 
this trend are substantially unknown. Studies evaluating 
the modification of muscle magnetic resonance imaging 
(MRI) through time as possible outcome measure have not 
Table 4  Multivariable regression models to evaluate determinants of Δ FSHD score
Multivariable regression models performed in the whole cohort, index cases and relatives. All the models were adjusted by age, sex, length of 
follow up, and FSHD score at baseline
Clinical category: (A) individuals presenting facial and scapular girdle muscle weakness typical of FSHD; (B) individuals with muscle weakness 
limited to scapular girdle or facial muscles; (C) asymptomatic/healthy individuals; (D) individuals with myopathic phenotype presenting clinical 
features not consistent with FSHD canonical phenotype
RU repeat unit, R2 coefficient of determination: % of Δ FSHD score explained by variables included in the multivariable regression model
a Coefficients from the multivariable regression model; they represent mean difference of the Δ FSHD score between the category and the refer-
ence level
b Reference level
c 95% confidence Interval
All cohort Index cases Carrier relatives
Betaa 95%  CIc Betaa 95%  CIc Betaa 95%  CIc
D4Z4 allele size (RU)
 Index cases Refb
 Carrier relatives − 0.64 (− 1.07; − 0.20)
 1–3 Refb Refb Refb
 4–5 − 1.05 (− 1.76; − 0.33) − 0.97 (− 1.99; 0.05) − 1.50 (− 2.43; − 0.56)
 6 − 1.11 (− 1.82; − 0.40) − 0.94 (− 1.97; 0.08) − 1.68 (− 2.59; − 0.76)
 7–8 − 1.42 (− 2.17; − 0.66) − 1.24 (− 2.33; − 0.15) − 2.12 (− 3.11; − 1.13)
 9–10 − 1.07 (− 1.87; − 0.26) − 1.05 (− 2.24; 0.15) − 1.52 (− 2.53; − 0.52)
Clinical category
 A Refb Refb Refb
 B − 1.45 (− 2.19; − 0.70) – – − 2.25 (− 3.08; − 1.42)
 C − 0.89 (− 1.59; − 0.18) − 0.91 (− 2.16; 0.33) − 1.64 (− 2.45; − 0.83)
 D 0.19 (− 0.39; 0.76) 0.51 (− 0.30; 1.32) − 0.80 (− 1.58; − 0.13)
R2 = 0.30 R2 = 0.12 R2 = 0.43
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given a definitive answer [32, 33]. No definite predictors 
of decline of muscle strength have been identified, apart 
from early disease onset [34].
To our knowledge, the present work is the largest long-
term clinical follow-up study in FSHD conducted on a 
cohort of individuals carrying D4Z4 reduced alleles.
We found that the clinical phenotype as described by 
the CCEF categories might be a predictor of the progres-
sion of disability with a more rapid evolution of disease in 
individuals presenting a classical FSHD phenotype (cat-
egory A) in comparison to patients with a facial-sparing 
phenotype (category B1). In this respect, previous studies 
suggested that the facial sparing phenotype in DRA car-
riers may represent a different nosological entity with a 
mild phenotype [23, 24]. Accordingly, Mah and collabo-
rators (2018), who studied individuals with early onset 
FSHD, considered that the disease has a slow progression 
in patients with facial sparing [16]. In the same work, the 
Authors concluded that earlier age at onset of facial weak-
ness was associated with greater disease severity. These 
patients, in our view, correspond, in our cohort, to indi-
viduals assessed as Category A1 who displayed the most 
severe phenotype and accelerated disease worsening.
Notably, the identification of non-FSHD signs in DRA 
carriers (category D) might serve as a proxy indicator of 
the co-presence of other genetic defects or modulators and 
requires additional studies and gene testing as indicated 
by the numerous cases reporting the association of FSHD 
with other neuromuscular conditions reviewed by Refs. 
[35–47]. Finally, asymptomatic/healthy carriers of 4–10 
RU D4Z4 alleles, classified as Category C, stay asymp-
tomatic/healthy in 79.1% of cases over the 5-year period.
Overall, the strong prognostic effect of the clinical 
phenotype as described by the CCEF categories, together 
with the size of the DRA, is confirmed by the multivari-
able models considering sex, age, age at onset, disease 
duration, DRA size. This effect is particularly significant 
among carrier relatives on whom the prognostic model 
explains the 42% of ΔFSHD score variability.
Our data substantially confirm, in the long-term, the 
clinical diversity previously observed between index cases 
and carrier relatives [7] and show that different disease 
progression might be anticipated in individuals assessed 
as different CCEF categories. The fact that muscle impair-
ment advances more rapidly in index cases in comparison 
with carrier relatives supports the notion that FSHD is a 
complex genetic disease with other elements, genetic and/
or environmental, influencing disease progression. These 
results complement our earlier observation showing that 
the proportion of penetrance inversely correlates with the 
degree of kinship, 72.5% in first degree carrier relatives 
versus 52.9% in second/fifth degree carrier relatives [7].
Finally, the detailed investigation of muscle strength by 
MRC grading scale indicates that tibialis anterior, deterio-
rates at high rate in 5 years. Thus, quantifiable assessment(s) 
might be designed on the evaluation of this muscle to cre-
ate sensitive and effective outcome measures able to detect 
small changes as sign of deterioration in a timeframe suit-
able for clinical trials.
Limitations of the study
Our work presents methodological limitations: not using 
CCEF for the first-visit assessment and not evaluating 
patients with MRI, which is sometimes planned in medical 
follow-up. The mean of the disease duration of the index 
cases is longer than carrier relatives. This is a selection bias 
that could influence the clinical impairment in the index 
cases.
At present tools that capture the clinical progression in 
a short period (such as 1 or 2 years of clinical trial) are not 
available. In the future, other studies may be conducted with 
the support of clinical assessment and including other vali-
dated outcome measures, such as long-term imaging data.
Conclusions
Our systematic study confirms the large intra-familial and 
inter-individual clinical variability observed in DRA carriers 
and demonstrates that the assessment of the CCEF catego-
ries might provide relevant information for the standard-
ized selection of patients eligible for clinical trials and for 
the stratification of individuals for clinical and molecular 
studies.
Molecular findings seem to have a good predictive value 
only for individuals carrying 1–3 DRA. Instead people car-
rying 4–10 DRA display large clinical variability ranging 
from healthy carrier relatives to individuals showing com-
plex myopathic phenotypes. This result, together with the 
knowledge that DRA with 4–8 RU have 3% frequency in the 
general population [31, 48, 49], should be considered in the 
guidelines for FSHD diagnosis [50].
Data reported here imply that the precise clinical descrip-
tion and genetic investigation are essential for the clinical 
management of pedigrees in which one DRA segregates. 
Indeed, the reduced risk of developing disease for healthy 
carrier relatives lessens the psychological burden of a posi-
tive molecular diagnosis and should sustain procreative deci-
sions. It is advisable to provide genetic counseling based on 
clinical and molecular evaluation of each family. For people 
at consultation, results of molecular analyses should be con-
sidered together with the clinical categories assessed in the 
family members, taking into account the degree of kinship 
towards the index cases, as well as the penetrance observed 
in each individual family, whenever possible.
Journal of Neurology 
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